Vitamin D metabolites are associated with clinical and MRI outcomes in multiple sclerosis patients

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 82, Issue 2, 2011, Pages 189-195

  Weinstock Guttman, Bianca ^a   Zivadinov, Robert ^a   Qu, Jun ^b   Cookfair, Diane ^a   Duan, Xiaotao ^b   Bang, Eunjin ^b   Bergsland, Niels ^a   Hussein, Sara ^a   Cherneva, Mariya ^a   Willis, Laura ^a   Heininen Brown, Mari ^a   Ramanathan, Murali ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLECALCIFEROL; ERGOCALCIFEROL; VITAMIN D;

ADULT; ARTICLE; BRAIN INJURY; BRAIN TISSUE; DISABILITY; DISEASE SEVERITY; FEMALE; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL;

24,25-DIHYDROXYVITAMIN D 3; 25-HYDROXYVITAMIN D 2; ADULT; CALCIFEDIOL; CALCITRIOL; CHROMATOGRAPHY, LIQUID; DISABILITY EVALUATION; DISEASE PROGRESSION; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIPLE SCLEROSIS; REGRESSION ANALYSIS; VITAMIN D;

EID: 78751580274     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp.2010.227942     Document Type: Article

References (43)

1. Ebers GC, Kukay K, Bulman DE, et al. A full genome search in multiple sclerosis. Nat Genet 1996;13:472-6.
2. Hafler DA, Compston A, Sawcer S, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med 2007;357:851-62.
3. Ascherio A, Munger KL. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann Neurol 2007;61:288-99.
4. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000;47:707-17.
5. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr Opin Neurol 1999;12:295-302. (Pubitemid 29378163)
6. van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol 2007;254:581-90. (Pubitemid 46781963)
7. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-5. (Pubitemid 38082871)
8. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-8.
9. Smolders J, Peelen E, Thewissen M, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev 2009;8:621-6.
10. van Etten E, Stoffels K, Gysemans C, et al. Regulation of vitamin D homeostasis: implications for the immune system. Nutr Rev 2008;66(10 Suppl 2):S125-34.
11. Smolders J, Thewissen M, Peelen E, et al. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009;4:e6635.
12. Royal W 3rd, Mia Y, Li H, et al. Peripheral blood regulatory T cell measurements correlate with serum vitamin D levels in patients with multiple sclerosis. J Neuroimmunol 2009;213:135-41.
13. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer 2007;7:684-700.
14. Duan X, Weinstock-Guttman B, Wang H, et al. Ultrasensitive quantification of serum vitamin D metabolites using selective solid-phase extraction coupled to microflow liquid chromatography and isotope-dilution mass spectrometry. Anal Chem 2010;82:2488-97.
15. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7.
16. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-6.
17. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11.
18. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008;71:136-44.
19. Zivadinov R, Weinstock-Guttman B, Hashmi K, et al. Smoking is associated with increased lesion volumes and brain atrophy in multiple sclerosis. Neurology 2009;73:504-10.
20. Zivadinov R, Weinstock-Guttman B, Zorzon M, et al. Gene-environment interactions between HLA B7/A2, EBV antibodies are associated with MRI injury in multiple sclerosis. J Neuroimmunol 2009;209:123-30.
21. Zivadinov R, Rudick RA, De Masi R, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001;57:1239-47.
22. Zivadinov R, Weinstock-Guttman B, Benedict R, et al. Preservation of gray matter volume in multiple sclerosis patients with the Met allele of the rs6265 (Val66Met) SNP of brain-derived neurotrophic factor. Hum Mol Genet 2007;16:2659-68. (Pubitemid 350018508)
23. van der Mei IA, Ponsonby AL, Engelsen O, et al. The high prevalence of vitamin D insufficiency across Australian populations is only partly explained by season and latitude. Environ Health Perspect 2007;115:1132-9.
24. Qu J, Qu Y, Straubinger RM. Ultra-sensitive quantification of corticosteroids in plasma samples using selective solid-phase extraction and reversed-phase capillary high-performance liquid chromatography/tandem mass spectrometry. Anal Chem 2007;79:3786-93. (Pubitemid 46799075)
25. Yu H, Straubinger RM, Cao J, et al. Ultra-sensitive quantification of paclitaxel using selective solid-phase extraction in conjunction with reversed-phase capillary liquid chromatography/tandem mass spectrometry. J Chromatogr A 2008;1210:160-7.
26. Qu J, Straubinger RM. Improved sensitivity for quantification of proteins using triply charged cleavable isotope-coded affinity tag peptides. Rapid Commun Mass Spectrom 2005;19:2857-64. (Pubitemid 41383371)
27. Aronov PA, Hall LM, Dettmer K, et al. Metabolic profiling of major vitamin D metabolites using Diels-Alder derivatization and ultra-performance liquid chromatography-tandem mass spectrometry. Anal Bioanal Chem 2008;391:1917-30.
28. Duan X, Young R, Straubinger RM, et al. A straightforward and highly efficient precipitation/on-pellet digestion procedure coupled with a long gradient nano-LC separation and Orbitrap mass spectrometry for label-free expression profiling of the swine heart mitochondrial proteome. J Proteome Res 2009;8:2838-50.
29. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004;29:664-73. (Pubitemid 39491265)
30. Kato A, Seo EG, Einhorn TA, et al. Studies on 24R,25-dihydroxyvitamin D3: evidence for a nonnuclear membrane receptor in the chick tibial fracture-healing callus. Bone 1998;23:141-6. (Pubitemid 28379875)
31. Seo EG, Einhorn TA, Norman AW. 24R,25-dihydroxyvitamin D3: an essential vitamin D3 metabolite for both normal bone integrity and healing of tibial fracture in chicks. Endocrinology 1997;138:3864-72.
32. Sakaki T, Kagawa N, Yamamoto K, et al. Metabolism of vitamin D3 by cytochromes P450. Front Biosci 2005;10:119-34.
33. Larsson D, Anderson D, Smith NM, et al. 24,25-dihydroxyvitamin D3 binds to catalase. J Cell Biochem 2006;97:1259-66.
34. Holmen J, Jansson A, Larsson D. A kinetic overview of the receptors involved in 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 signaling: a systems biology approach. Crit Rev Eukaryot Gene Expr 2009;19:181-96.
35. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67:618-24.
36. Orton SM, Morris AP, Herrera BM, et al. Evidence for genetic regulation of vitamin D status in twins with multiple sclerosis. Am J Clin Nutr 2008;88:441-7.
37. Sadovnick AD, Ebers GC, Dyment DA, et al. Evidence for genetic basis of multiple sclerosis. The Canadian Collaborative Study Group. Lancet 1996;347:1728-30.
38. Fukazawa T, Yabe I, Kikuchi S, et al. Association of vitamin D receptor gene polymorphism with multiple sclerosis in Japanese. J Neurol Sci 1999;166:47-52. (Pubitemid 29327245)
39. Fu L, Yun F, Oczak M, et al. Common genetic variants of the vitamin D binding protein (DBP) predict differences in response of serum 25-hydroxyvitamin D [25(OH) D] to vitamin D supplementation. Clin Biochem 2009;42:1174-7.
40. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet 2009;5:e1000369.
41. Ramagopalan SV, Heger A, Berlanga AJ, et al. A ChIP-seq defined genome-wide map of vitamin D receptor binding: Associations with disease and evolution. Genome Res 2010;20:1352-60.
42. Hiremath GS, Cettomai D, Baynes M, et al. Vitamin D status and effect of low-dose cholecalciferol and high-dose ergocalciferol supplementation in multiple sclerosis. Mult Scler 2009;15:735-40.
43. Bischoff-Ferrari HA, Dawson-Hughes B. Where do we stand on vitamin D? Bone 2007;41(1 Suppl 1):S13-19.